Vertex planning regulatory applications for Kalydeco in children with CF ages 1-2

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) plans to submit regulatory applications this quarter to FDA and EMA to expand the label of Kalydeco ivacaftor (VX-770) to include treatment of

Read the full 270 word article

User Sign In